Futibatinib

Last Updated: 04/28/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 100 publications

The evolving role of futibatinib for advanced cholangiocarcinoma.

The evolving role of futibatinib for advanced cholangiocarcinoma.

Journal: Expert review of gastroenterology & hepatology
Published: March 23, 2026

Pharmacovigilance analysis of the FGFR inhibitor futibatinib using the FDA adverse event reporting system (FAERS) database.

Pharmacovigilance analysis of the FGFR inhibitor futibatinib using the FDA adverse event reporting system (FAERS) database.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
Published: March 21, 2026

Management of Nail Toxicities From Fibroblast Growth Factor Receptor Inhibitors.

Management of Nail Toxicities From Fibroblast Growth Factor Receptor Inhibitors.

Journal: Journal of drugs in dermatology : JDD
Published: March 04, 2026

Mutated FGFR1 is an oncogenic driver and therapeutic target in high-risk neuroblastoma.

Mutated FGFR1 is an oncogenic driver and therapeutic target in high-risk neuroblastoma.

Journal: The Journal of clinical investigation
Published: February 12, 2026

Design, Synthesis, and Biological Evaluation of the First Novel Macrocycle-Based FGFR Inhibitors That Overcome Clinically Acquired Resistance.

Design, Synthesis, and Biological Evaluation of the First Novel Macrocycle-Based FGFR Inhibitors That Overcome Clinically Acquired Resistance.

Journal: Journal of medicinal chemistry
Published: January 06, 2026

FGFR2-Rearranged Biliary Tract Cancer: Biology, Resistance Mechanisms, and Emerging Therapeutic Strategies.

FGFR2-Rearranged Biliary Tract Cancer: Biology, Resistance Mechanisms, and Emerging Therapeutic Strategies.

Journal: Cancers
Published: December 29, 2025

Acquired FGFR2 mutation leads resistance to pemigatinib in a patient with FGFR2-driven Borrmann type IV gastric cancer.

Acquired FGFR2 mutation leads resistance to pemigatinib in a patient with FGFR2-driven Borrmann type IV gastric cancer.

Journal: Anti-cancer drugs
Published: December 03, 2025

Recurrent Resistance Mutations to Lirafugratinib Inform Treatment Sequencing in FGFR2-Driven Tumors.

Recurrent Resistance Mutations to Lirafugratinib Inform Treatment Sequencing in FGFR2-Driven Tumors.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 15, 2025

Cholangiocarcinoma - Morphology, Immunohistochemistry, and Genetics.

Cholangiocarcinoma - Morphology, Immunohistochemistry, and Genetics.

Journal: Ceskoslovenska patologie
Published: October 16, 2025

Fibroblast growth factor receptor inhibitors in glioma: a narrative review of recent advances.

Fibroblast growth factor receptor inhibitors in glioma: a narrative review of recent advances.

Journal: Frontiers in pharmacology
Published: September 28, 2025

Expanding Horizons in Cholangiocarcinoma: Emerging Targets Beyond FGFR2 and IDH1.

Expanding Horizons in Cholangiocarcinoma: Emerging Targets Beyond FGFR2 and IDH1.

Journal: International journal of molecular sciences
Published: September 17, 2025

Lenvatinib after progression on pemigatinib and futibatinib in FGFR2 fusion-positive biliary tract cancer with an acquired kinase point mutation.

Lenvatinib after progression on pemigatinib and futibatinib in FGFR2 fusion-positive biliary tract cancer with an acquired kinase point mutation.

Journal: The oncologist
Published: August 18, 2025
Showing 1-12 of 100

Last Updated: 04/28/2026